More patients with type 2 diabetes reach target lipid levels with combination therapy

A significantly greater proportion of patients with type 2 diabetes with mixed dyslipidemia treated with a combination of fenofibric acid and rosuvastatin achieved American Diabetes Association (ADA) target lipid levels compared to those taking rosuvastatin alone, reports Robert S. Rosenson, MD, State University of New York, Brooklyn, NY (pictured left). "Because diabetes is a risk factor for heart disease, it is particularly important that patients with diabetes and mixed dyslipidemia manage all three key lipid parameters," he says. Click here for full article.